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Abstract
Background: One method to understand and evaluate an experiment that produces a large set of genes, such as
a gene expression microarray analysis, is to identify overrepresentation or enrichment for biological pathways.
Because pathways are able to functionally describe the set of genes, much effort has been made to collect curated
biological pathways into publicly accessible databases. When combining disparate databases, highly related or
redundant pathways exist, making their consolidation into pathway concepts essential. This will facilitate unbiased,
comprehensive yet streamlined analysis of experiments that result in large gene sets.
Methods: After gene set enrichment finds representative pathways for large gene sets, pathways are consolidated
into representative pathway concepts. Three complementary, but different methods of pathway consolidation are
explored. Enrichment Consolidation combines the set of the pathways enriched for the signature gene list through
iterative combining of enriched pathways with other pathways with similar signature gene sets; Weighted
Consolidation utilizes a Protein-Protein Interaction network based gene-weighting approach that finds clusters of
both enriched and non-enriched pathways limited to the experiments’ resultant gene list; and finally the de novo
Consolidation method uses several measurements of pathway similarity, that finds static pathway clusters
independent of any given experiment.
Results: We demonstrate that the three consolidation methods provide unified yet different functional insights of
a resultant gene set derived from a genome-wide profiling experiment. Results from the methods are presented,
demonstrating their applications in biological studies and comparing with a pathway web-based framework that
also combines several pathway databases. Additionally a web-based consolidation framework that encompasses all
three methods discussed in this paper, Pathway Distiller (http://cbbiweb.uthscsa.edu/PathwayDistiller), is established
to allow researchers access to the methods and example microarray data described in this manuscript, and the
ability to analyze their own gene list by using our unique consolidation methods.
Conclusions: By combining several pathway systems, implementing different, but complementary pathway
consolidation methods, and providing a user-friendly web-accessible tool, we have enabled users the ability to
extract functional explanations of their genome wide experiments.
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Background
There exist several public data sources such as Biocarta
[1], KEGG [2], WikiPathways [3], Pathway Commons [4],
NCBI’s Biosystems [5], NCI Nature [6], Reactome [7] and
HumanCyc(a member of the BioCyc database) [8] for
pathway annotations including cellular process, metabolic
process, molecular function, and physiological process.
These data sources also provide a variety of information
ranging from simple formats, for example a list of genes
involved in a specific pathway, to complex information,
like the directed graph of biological entities and their effect
on each other. There also exist private data sources like
Ingenuity [9], Pathway Studios [10], and Protein Lounge
(http://www.proteinlounge.com) however they are not
freely available.
Pathway information can offer insights for a variety of
research including genome-wide gene expression analysis.
Gene expression levels detected by microarrays and Next
Generation Sequencing (NGS) allow the profiling of gene
products that are differentiated between diverse condi-
tions. Likewise, genomic copy number alteration, differen-
tial methylation, and other genome-wide profiling
experiments result in a list of resultant genes with the
capacity to differentiate phenotypic or treatment condi-
tions. Often biological concepts are used to describe gene
lists [11,12]. The concepts are unifying characteristics that
are statistically enriched for the gene list and provide func-
tional insight related to the gene list. Any concept that has
a predefined list of genes matching some or all of the
experiment’s resultant genes is considered enriched and
the level of enrichment is statistically quantifiable (relative
to random selection). Selection of pathways (concepts)
based on the statistical significant enrichment score (ES) is
one natural way to infer function from gene expression
patterns. Gene Set Enrichment Analysis (GSEA) [13]
introduced a Kolmogorov-Smirnov like method that finds
enriched pathways by statistical analysis of genes that can
be ordered by measurement such as expression fold
change. However when no ordering measurement is avail-
able, some other means, like Fisher’s Exact test is neces-
sary to find enriched pathways.
The development of many genome-wide profiling tech-
nologies and the number of pathway data sources has lead
to an explosion in the number of pathways to be studied
from a single gene set. Chowbina et al. [14] discuss the
integration of multiple data sources to determine a single
collection of pathways that provides functional insight for
experimental gene sets. Additionally, they provide an
online database (HPD) to give users access to their inte-
grated pathway database containing 999 human pathways.
Yu et al. [15] have combined several pathway database to
create another integrated pathway database (hiPathDB)
with 1661 human pathways. To create a similar database,
we downloaded pathways from BioCarta, Pathway
Commons, NCBI BioSystems, and WikiPathways, and
after removing pathways with no gene members, 2,462
pathways remain (as of February 2012) from specific
sources including WikiPathways, Reactome, KEGG, NCI
Nature, BioCarta and HumanCyc. Our database contains
all of the pathway sources of HPD and hiPathDB except
Protein Lounge which is not publically available. While
larger collection of pathways may appear to be better
starting point, the interdependency and/or redundancy
within and between databases will skew the statistical
assessment of a large gene set and lead to incorrect func-
tional associations. A better solution would be to consoli-
date the complete list of pathways as non-redundant and
representative pathways, enabling better understanding of
any experiment including gene set enrichment results.
A natural way to combine lists is by parsing the pathway
names, for example, KEGG, Reactome and WikiPathways
all contain “Apoptosis”. However in this instance although
the pathway names are the same, the gene sets are differ-
ent. Name matching by itself also misses exact gene set
matches. “Synthesis and Degradation of Ketone Bodies”
from WikiPathways and “Ketone body metabolism” from
Pathway Commons contain exactly the same 5 genes. This
match would be missed if simple name matching were
employed.
Another natural method of pathway consolidation finds
some overlap between the gene members of pathways
pairs, including exact gene set matches. By observing the
same gene set in two pathways they could be consolidated
into a single representative pathway. For example, three
separate Reactome pathways contain the exact same gene
members, “SMAC binds to IAPs”, “SMAC-mediated apop-
totic response”, and “SMAC-mediated dissociation of IAP:
caspase complexes”. Like the previous example, all three
pathways could be consolidated into one “pathway con-
cept” simply by observing the identical gene membership
in sets. Among the 2,462 pathways, 312 have exactly the
same gene members with at least one other pathway,
forming 136 distinct groups. This method would reduce
the number of pathways somewhat (2,462 - 312 + 136 =
2,286). To consolidate further, pathways that are similar
could be combined when they have sufficiently similar
gene sets, however the difficulty is determination of “suffi-
ciently similar”.
A naïve way of determining “sufficient similarity” is by
using subset relationship. For example, “Regulation of
RhebGTPase activity by AMPK” from Reactome contains
10 genes that are all present in the “Insulin Signaling”
pathway from KEGG with 138 genes. This situation is
typical when aggregating data sources that contain gen-
eral pathways and pathways that represent specific sub-
pathways of the general pathways. Of the 2,462 pathways,
1,681 of them are exact subsets of at least one other path-
way. While this might seem to offer a way to significantly
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consolidate pathways, there exist overlapping pathway
gene sets that make consolidation difficult. For example,
“Endothelins” from NCI Nature and “TRAIL signaling
pathway” of NCI Nature contain all of the 22 genes of
the “IL6 pathway” from BioCarta, but “Endothelins” and
“TRAIL signaling pathway” are not subsets of each other,
making it impossible to combine them by grouping sub-
sets with supersets. Therefore “IL6 pathway” cannot be
labelled as a subset of a single pathway, in this case only
as a subset of two pathways.
In addition to membership comparison, several meth-
ods have been proposed to accomplish pathway cluster-
ing by pathway activity similarity (expression, disease
phenotypes, etc). Mamitsuka et al. [16] proposed a
method based on Markov mixture models that relies on
microarray expression and the graph of a metabolic path-
way. Li et al. [17] proposed a method that clusters sub-
pathways according to diseases. Because of the diversity
of representations of pathways among the publically
available databases, we relied on the most simple repre-
sentation of pathways, their gene members. Similarly, it is
possible to find microarray expression values for the gene
members, like Fang et al. [18], however we chose to keep
our gene sets unbiased for specific microarray studies.
While this information might be advantageous in specific
applications, for many systems biology studies, a generic
approach is desired.
One online integrate pathway repository, HPD [14],
computes a similarity score for all pathway pairs based
on overlapping gene sets. A user then can visualize the
scores in an “Association Table”. Through visualization a
user would be able to see similar pathways. Another
repository, hiPathDB, only lists all of the pathways that
contain at least one of the input genes with no means for
determining pathway overlap. We propose three different
methods to consolidate multiple pathways into one path-
way concept. Each provides a slightly different analysis of
the concepts describing a single experiment. Figure 1
illustrates how different methods of analysis can draw
attention to different aspects of the same data. Hierarchi-
cal clustering by Gene Expression (Figure 1A) shows how
the absolute expression values for each gene changes
over the time course data. Alternatively, clustering by
Pathway Expression (Figure 1B) highlights pathway activ-
ity over the time course data. Taken together, they pro-
vide complementary, but different views of the same
data. Our consolidation methods also provide comple-
mentary, but different views of the pathway concepts that
represent an experiment’s resultant gene set. One is
tightly associated with the results from gene expression
experiments consolidating only enriched pathways.
Another uses pathway pair scoring, comparing not only
the overlap of the resultant genes, but also weighting by
shared interactions between the pathways. This method
consolidates both enriched and non-enriched pathways.
The third method, independent of any given resultant
gene set, combines pathways with other pathways using
their gene member and the gene member annotations
like ontology or interacting pairs. The first and second
pathway consolidation methods combine gene set mem-
bership and gene expression analysis to create a consoli-
dated list of pathways specific to the condition studied in
the analysis. Therefore, it is tailored to a specific experi-
ment. The third measures the overlap of two sets by a
variety of criteria and then groups pathways with the
greatest similarity. This creates a set of grouped pathways
independent of any experiment that is used for gene set
enrichment.
Methods
Data collection
All human pathway data presented here were down-
loaded from four primary data repositories, BioCarta,
WikiPathways, NCBI BioSystems and Pathway Com-
mons representing six data sets (update to February
2012). BioCarta (BioCarta), KEGG (obtained via NCBI
BioSystems), NCI Nature (obtained via Pathway Com-
mons) and HumanCyc (obtained via Pathway Com-
mons) were contained in one of the data sources as
indicated, however Reactome (covered by both NCBI
BioSystems and Pathway Commons) and WikiPathways
(covered by both WikiPathways and NCBI BioSystems)
were contained in two different repositories. For those
situations where the names matched between sources
the gene identifiers were combined. 2,665 pathways
were determined from BioCarta, KEGG, NCI Nature,
WikiPathways, Reactome and HumanCyc. 203 pathways
with no gene members were removed leaving 2,462
pathways with at least one gene member.
Annotations including Gene Ontology (GO) [19] and
protein interactions [20] were downloaded along with
GO Slim annotations for the GO entries.
Two gene expression data sets were obtained. The first
[21] was used to test our consolidation methods and is
provided as an example in the Pathway Distiller frame-
work. Gene expression profiles by Affymetrix HG-U95Av2
were measured at five different time points after treatment
with cisplatin in the human ovarian cancer cell A2780.
After normalization and filtering steps, thresholding of
log-fold-change at 1.0 was performed to generate 5 differ-
entially expressed gene sets that were further combined to
form a single resultant gene set (total of 526 genes) that
represents this experiment over any time point. The back-
ground gene set contained all of the probes of Affymetrix
HG-U95Av2, regardless of expression level that map to
NCBI Entrez GeneIDs (total of 8000 genes).
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Pathway enrichment and consolidation
One-sided Fisher’s Exact test finds p-values for all path-
ways that contains at least 1 of the user supplied resultant
gene set compared to the human genome or a user sup-
plied background gene set. Three methods were developed
to focus on different but complementary cluster types for
the resulting pathways. One method focuses only on
enriched pathways unique to the experiment’s resultant
gene set. Another method clusters both enriched and non-
enriched pathways using scores derived from interactions
within each pathway involving the resultant genes. The
final method independent of the resultant gene set finds
cluster of pathways based on gene membership, GO ontol-
ogy and protein-protein interactions. This is the only
method that can be pre-determined, independent of
experiments’ resultant gene lists.
A. Consolidation of enriched pathways
Given the initial resultant gene set and the initial most
enriched pathway, we iteratively reduce the list of
enriched pathways and the resultant gene set by remov-
ing the genes in the most enriched pathway from the
resultant gene set and recomputing enrichment p-values
for the remaining pathways using the reduced gene set.
Any pathway that is no longer enriched is consolidated
with the most enriched pathway for this iteration.
Because each iteration starts with removal of shared
genes based on enrichment p-values, the order of gene
removal is different for each resultant gene set and
therefore specific to that experiment. We perform the
consolidation procedure as follows,
Pathway Consolidation Procedure 1: Enrichment
Consolidation
1) Start with a set of all enriched pathways (each path-
way is defined as a collection of genes, or si = {gi}), or
S0 = {si: pi_Fisher(D) ≤ 0.05}, where D is the differential
expressed gene set or resultant gene set, pi_Fisher is the
enrichment p-value of pathway si in gene set D; a set
Figure 1 Hierarchical clustering of expression data at gene level and pathway level. Hierarchical clustering of (A) absolute gene expression
over 5 time points; and (B) pathway expression. Gene expression of samples at 5 different time points (TP1 to TP5) are marked above the
heatmap, log2-transformed and normalized gene expression data of each gene were plotted in Figure 1A. Average of absolute gene expression
over each pathway were evaluated and then plotted in Figure 1B to reflect the activities of biological pathways.
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of genes supporting all pathways, or G0 = {gk: gk Î any
si}, and initialized the selected pathways set P
0 = ∅;
2) Find the most enriched pathway sj where sj Î S
0 &
pj ≤ pi, for all i ≠ j;
3) Upon obtaining sj, we update S
1 = {S0\sj}, G
1 =
{G0\gk; gk Î sj}, and selected pathway set P
1 = P0 ∪ {sj};
4) Update pathway enrichment p-values, since we
removed genes contained in sj from all other
pathways;
5) Update remaining pathway set by removing non-
significant pathways after removing genes contained in
previous enriched pathway, S1 = {S1\si: pi_Fisher(D) >
0.05}; and
6) Repeat steps 2-5, stop when Sm = ∅.
By starting with the most enriched pathway each itera-
tion, each pathway concept is represented by the most
enriched pathways for the resultant gene set.
B. Weighted consolidation with resultant genes
Weighted Consolidation first orders pathway pairs by
scores that incorporate information about the number of
overlapping resultant genes and the interactions among
those resultant genes. Second, it adds each pair from high-
est to lowest score into a cluster. For weighting we
followed the method outlined by Fang et al. [18] to deter-
mine weight (Wi) for each gene (gi) within each of the
pathways (sj) by comparing the number of known and pre-
dicted interactions [20] between gi and the other genes in
sj, against the number of known and predicted interactions
between gi and the other genes in the genome. Suppose
that gi has no specific functional association with genes in
pathway sj; then the number of interactions Xi of gi to
others in a given pathway is expected to follow a hyper-
geometric distribution,
P(Xi = x|N,Mi,Kj) =
(
Mi
x
)(
N − Mi
Kj − x
)
(
N
Kj
) (1)
where Mi is the number of interactions of gi to others
in the genome, N is the number genes in the genome,
and Kj is the number of genes in pathway sj with the
expected number of interactions E(Xi) of gene i derived
as
E(Xi) =
MiKj
N
(2)
for gene gi, i = 1, 2, ..., Kj. The observed number of
interactions between genes in sj is likely to be signifi-
cantly larger than E(Xi), when there is a specific function
association of gi in pathway sj, thus a larger weight. In
the algorithm, they rescaled this weight to quantify the
relative association strength Wi of gi as,
wi = Xi − E(Xi), (3)
Wi =
{
log2(wi + 2), wi > 0
1, wi ≤ 0 (4)
Although Fang et al. included co-expression and func-
tional annotation associations between genes, we limited
the association count to the interactions found in one of
our earlier implementations of the protein interaction
database, InterologFinder [8,20]. Gene expression could
be determined for the gene members, however the
experiments themselves are tissue and condition speci-
fic. We chose to leave Pathway Distiller unbiased for
any one experiment by not incorporating gene expres-
sion information.
The pathway consolidation procedure is implemented
by utilizing a similarity score confined to the resultant
gene set, D, with weights generated from the number of
interactions within a given pathway. Upon obtaining a
similarity score (Eq. 5) for each pathway pair, we itera-
tively process the pathway pairs from high to low scores
either adding them to existing clusters or forming a new
cluster with the pair. Specifically, we perform the conso-
lidation procedure as follows,
Pathway Consolidation Procedure 2: Weighted
Consolidation
1) Start with a set of all pathways (each pathway is
defined as a collection of genes, or si = {gi}, each
gene within si has a unique weight wi according to
its relative association with the other genes in path-
way si as described in Eqs. (1-4); a resultant gene set,
D, is also required;
2) Determine a similarity score for each pathway
pair where the weights for overlapping resultant
genes between the pathways are compared against
the weights between all resultant genes in the path-
way pair,
Similarity(si, sj) =
∑
gk∈(si∩sj∩D) wk∑
gk∈((si∪sj)∩D) wk
(5)
3) For each unique pathway pair, ordered by their
similarity score, add one, both or neither pathway to
a cluster ck that is a member of all clusters C = {ck}
and made up of a set of pathways.
a. If neither si nor sj already belong to a cluster
in C, create a new cluster c’ = {si, sj}, add cluster
c’ to C;
b. If si is an element of ck, but sj is not a member
of any cluster in C, add sj to ck, similarly handled
vice versa;
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c. If both si and sj are members of any cluster
in C, do nothing.
4) Repeat Step 3) for all pathway pairs.
C. De novo pathway clustering
To cluster pathways without experimental information, a
hierarchical clustering-based method was developed in
MATLAB using the Statistics Toolbox (Mathworks,
Natick, MA). After finding similarity measurements
between pathways, the linkage algorithm is used to link
pairs of pathways to form a hierarchical cluster tree. The
Cluster function was used to either choose a particular
cut-off threshold for groupings, or to choose how many
clusters the user desires. As shown in Figure 2, the clus-
tering is effectively a horizontal cut of the clustering den-
drogram. The number of clusters is relative to the
minimum Jaccard coefficient [22] threshold required to
combine clusters when each pathway starts in its own
cluster. By choosing different cluster count thresholds,
the user can have different similarity requirements. The
lower the cut-off threshold the fewer the number of clus-
ters and the more pathways grouped in each cluster. To
find an actual measure of pathway similarity, the Jaccard
coefficient and distance are used as shown in (6) and (7).
J(si, sj) =
|Ai ∩ Aj|
|Ai ∪ Aj| (6)
di,j = 1 − J(si, sj) (7)
where |·| is the cardinality of a set, and si and sj are ith
and jth pathways similarly defined earlier, and Ai and Aj
are attributes of genes in pathways si and sj. A total of
three different gene attributes were looked at as the
common term: 1) gene membership, 2) “Guilt-by-func-
tion” via Gene Ontology, and 3) “Guilt-by-association”
via protein-protein interactants. Our algorithm handles
all in the same manner by finding the Jaccard distance
between two pathways based on set commonality. This
forms a Jaccard matrix, that represents the similarities
between all pathways.
For pathway consolidation based on Gene Ontology
and protein-protein interactions, a map was created to
link pathways to GoSlim terms, and to protein-protein
interactants creating new member sets from the original
sets used in (6) and (7). Or
Ai(sj) ←
⎧⎨
⎩
{gi; gi ∈ sj}⋃
gi∈sj GOSlim(gi)⋃
gi∈sj PPI(gi)
(8)
The mapping in (8) takes each gene in the pathway, or
creates a new set including the GoSlim ancestors of the
original gene’s GO terms, GOSlim(si); or creates a new
set including any gene that is known to interact with
the genes known to be in the pathway PPI(si). The exact
procedure is follows,
Figure 2 Hierarchical clusters of aggregated pathways. Dendrogram generated by using PPI similarity measurement and 250 clusters were
colored automatically to illustrated grouping effect.
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Pathway Consolidation Procedure 3: de novo
Consolidation
1) Start with a set of all pathways (each pathway is
defined as a collection of genes), or si = {gi}.
2) Determine the method of similarity measure
(membership, guilt-by-function, or guilt-by-associa-
tion, Eq. 8), and then evaluation Jaccard coefficient
by Eqs. 6-7;
3) Perform hierarchical clustering to obtain desired
specificity of pathway clusters defined by the user.
User indicates Jaccard Score cut-off, which defines
the clustering stop point.
Pathway distiller framework
We developed a web-based application, the Pathway
Distiller (http://cbbiweb.uthscsa.edu/PathwayDistiller),
which provides access to our integrated pathway data-
base base, pathway enrichment and three methods of
pathway consolidation. It builds on the Sidekick [23] fra-
mework. Pathway Distiller was built using Adobe Flex
and Action Script 3 which produces a Adobe Flash
movie that runs in a user’s web browser. The back-end
automatic data download, processing and query avail-
ability was created using the SideCache [24] framework
that is implemented in Java and designed to run as a
Java Servlet in a container such as Apache Tomcat [25].
Users can upload a set of genes (resultant gene set) to
access all components of the Pathway Distiller functions
or use a supplied sample gene set. The de novo pathway
clusters are also available for download.
Results
Using the Pathway Distiller framework as outlined in
Figure 3, we describe the process of taking a resultant
gene list (e.g., derived from a differential expression ana-
lysis method) and finding enriched pathway concepts (a
set of pathways derived from a consolidation procedure)
that provide function insights for the genomic data.
Further, we outline how the various consolidation meth-
ods find different descriptions of the resulting pathway
concepts related to the supplied resultant gene list.
Cisplatin case study and framework use case
The web-based application, Pathway Distiller, as shown
in Figure 3 and accessible at http://cbbiweb.uthscsa.edu/
PathwayDistiller, facilitates resultant gene set analysis
using pathway enrichment and consolidation. Using the
supplied cisplatin resultant gene set as a Use Case, we
import (1. Click) the 526 differential expressed genes
induced by cisplatin treatment (see Methods) and the
Figure 3 Pathway distiller screen shot of sample analysis. Steps for a typical resultant gene list analysis and pathway cluster discovery. Step
1: click to use sample resultant gene set. Step 2: click to use sample background set. Step 3: check all pathways. Step 4: click to do one-sided
Fisher’s Exact pathway enrichment; fill Enrichment Results grid. Step 5: click to do pathway consolidation; fills Consolidation Results grid; shows
default consolidation method. Step 6: click to select from consolidation methods.
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8000 background genes (2. Click). The user is able to
upload their own resultant gene set and background gene
set using the Upload File button. The background gene
set could be all of the probes for a given microarray plat-
form, while the resultant gene set would include only the
differentially expressed genes. By default (or when back-
ground gene set is not presented), the entire gene set of
human genome will be used as the background. In Step 3
(3. Check) we leave the default option (All) to find the
enrichment score for each of the 2,462 pathways main-
tained by our backend data management module. The
user is able to limit the pathway sources. Step 4 (4. Click)
fills the Enrichment Results grid with the pathways with
at least one of the resultant genes. For the cisplatin case
study, this results in 1456 pathways. Step 5 (5. Click) fills
the Consolidation Results grid. The default method, Path-
way Enrichment (EC), provides the 12 pathway concepts
mostly closely aligned with the Enrichment Results. Step 6
(6. Choose) displays the results of the other consolidation
methods. Additional features of Pathway Distiller include
flexible viewing options and links to external data sources
for most of the pathways and genes. A more thorough use
case is available on the Pathway Distiller website including
screen shots explaining Pathway Distiller’s functionality.
In our cisplatin case study, by sorting the grid by enrich-
ment score, 177 pathways were found to be significantly
enriched with p-value ≤ 0.05 (one-sided Fisher’s Exact
test). After the pathways are consolidated, the user is able
to choose from all of the consolidation methods using the
Consolidation Method drop down box. This displays the
pathway concepts (clusters), their member pathways,
the clustering score and the number of pathways within
the pathway concept. Each pathway concept, is labelled
with the most significant pathway in the group. The clus-
tering score for each method is the lowest enrichment
score of the individual pathways within the cluster.
For our cisplatin example, the Consolidation Results grid
first displays the EC consolidation results providing insight
into the similarity of the significantly enriched pathways
highly according to the resultant gene list’s pathway
enrichment. By choosing the Weighted Consolidation
(WC) option, the user finds pathway concepts related to
the specific input resultant gene set, however it includes
all of the 1,456 pathways with at least one cisplatin-
induced differentially expressed gene. Of the 12 pathway
concepts for the EC method, 1 of them contains 128 path-
ways and 4 of them contain a single pathway. The WC
method finds a maximum of 29 and minimum of 2 path-
ways in the 318 pathway concepts.
When more specific functional insights are required, by
choosing from the 3 de novo Consolidation methods (DC)
a user is able to have more fine-tuned control of both the
means to measure pathway similarity and the number of
concepts to determine. The DC naming convention Path-
way Distiller uses is as follows, the first half of each option
in Step 6 indicates the gene attribute from which the Jac-
card score is derived. Specifically, membership will provide
gene membership, GoSlim “Guilt-by-function” via Gene
Ontology, and PPI “Guilt-by-association” via gene interac-
tions. Each attribute is further subdivided into 8 cluster
count thresholds indicated in the second half of the DC
naming convention. Cut-offs of 5, 10, 20, 40, 50, 100, 200
and 500 provide the user fined-tuned control of the num-
ber of expected clusters and the resulting size of each clus-
ter. Together with EC and WC, the DC results for the
cisplatin-induced differentially expressed genes are
described in the first two columns of Table 1. In Step 6,
choosing GOSlim10 (maximum of 10 concepts weighted
by functional similarity) displays the 2 pathway concepts
with at least one of the 1456 pathways (Table 1 column 1).
Of these two concepts only one of them contains a signifi-
cantly enriched pathway (Table 1 column 2). member-
ship10 and PPI10 each only produce 1 concept that
overlaps the pathways with at least 1 cisplatin resultant
gene. In Step 6, GOSlim100 (maximum of 100 concepts)
displays the 51 pathway concepts with at least one of the
1456 pathways and by sorting 8 of them contain at least
one enriched pathway. Summarized in the Table, member-
ship100 and PPI100 find larger number of concepts than
their corresponding 10 cut-offs (42 and 16 respectively)
Table 1 Pathway cluster counts for cisplatin resultant gene set
Method Number of Pathway
Concept
Number of Concepts with
Enriched Pathways
Min number of pathways
in a concept
Max number of pathways
in a concept
Enrichment
Consolidation
12 12 1 128
Weighted Consolidation 318 74 2 29
GOSlim10,
membership10, PPI10
2, 1, 3 1, 1, 1 1, n/a, 1 1456, 1456, 1453
GOSlim100,
membership100, PPI100
51, 42, 16 8, 10, 2 1, 1, 1 1116, 793, 1248
GOSlim500,
membership500, PPI500
215, 263, 194 21, 46, 24 1, 1, 1 727, 79, 560
Note: n/a - indicates all pathways formed a single cluster
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and of these even fewer contain enriched pathways (10
and 2 respectively). The final DC type/cut-off combination
of 500 for GOSlim, membership and PPI finds 215, 263,
and 194 concepts with 21, 46, and 24 concepts with at
least one enriched pathway for each, respectively.
As expected in the fine-tuning of the DC methods the
maximal number of pathways in pathway concepts
decreases as the number of pathways increases. For
example all of the 1456 pathways with at least one cis-
platin induced differentially expressed gene are clustered
together for GOSlim10, however the maximal number
of pathways in a pathway concept for GOSlim500 is
727. In Table 1, we additionally provide results for
allowing 100 and 500 clusters to demonstrate the incre-
mental gain of number of pathway concepts, thus pro-
vide precise description of the input gene set.
The correct cut-off level is dependent on the user’s
needs both in terms acceptable size and number of clus-
ters and interest in specific pathways. For example, if a
user is interested in a specific group of pathways using a
lower cut-off like 40 combines them into the same clus-
ter with very few other pathways, this cut-off would be
appropriate. In membership40, the Sphingolipid metabo-
lism cluster contains only 6 pathways which is very
manageable. However, at the same cut-off, the Nucleo-
tide Metabolism cluster contains 170 which might be
too large to inspect. Using membership100 reduces the
Nucleotide Metabolism cluster to 19 pathways.
We investigated whether the pathway concepts
obtained from the EC and WC algorithms are significant
when compared to random draws of the same number
of genes from the genome. We assume that genes con-
tained in these pathways concepts show much stronger
interaction, comparing to genes randomly selected from
the genome. Table 2 shows the p-values of the number
interactions of genes within pathways concepts when
comparing to the same number of genes drawn at ran-
dom 1000 times. Other than 3 pathway concepts
(Methionine Degradation I, Nucleotide Metabolism, and
Vitamin C in the Brain pathways), genes in most path-
way concepts show significantly strong interaction.
Overview of Table 3-6 organization
Tables 3, 4, 5, 6 show results from a variety of resultant
gene sets. The tables are organized with rows of path-
ways and in each column how the pathways are grouped
in that consolidation method. The columns are divided
to facilitate reading the tables in column-wise directions.
In other words, the divisions of a column show how one
clustering methods groups the pathway rows. Each divi-
sion represents a pathway concept. Pathways that do
not consolidate into pathway concepts are not contained
in their own division and do not share similar symbols.
p53 related pathway analysis
As a drill-down example, Table 3 shows consolidation
results of seven pathways related to p53. Cisplatin is one
of the most effective and widely used anticancer drugs.
It is generally considered as a cytotoxic drug which kills
cancer cells by damaging DNA and inhibiting DNA
synthesis. On the other hand, the tumor suppressor pro-
tein p53 is considered as the “guardian of genome”[26].
It plays a critical role in eliciting cellular responses to
cisplatin-induced DNA damage. To start the de novo
consolidation, the de novo clustering methods based on
gene membership, Gene Ontology, and protein-protein
interaction were set for 500 clusters (membership500,
GOSlim500 and PPI500). For de novo Membership, 3
pathway concepts were obtained (■, ▲, and ●) contain-
ing 2, 1 and 4 pathways respectively. Similarly, de novo
Gene Ontology groups these pathways into 2 pathway
concepts (■ and ●) with 3 and 4 pathways respectively.
Table 2 Cluster estimation of randomness results
Pathway Enriched Consolidation p-value* Weighted Consolidation p-value*
Androgen Receptor Signaling Pathway < 10-150 < 10-150
ATM Signaling Pathway < 10-150 < 10-150
Cell Cycle, Mitotic < 10-150 < 10-150
Formation of Incision Complex in GG-NER 1.81 × 10-11 2.11 × 10-13
Glypican Pathway < 10-150 < 10-150
Lymphocyte TarBase 3.51 × 10-19 < 10-150
Methionine Degradation I (tohomocysteine) 2.40 × 10-4 0.14
mRNA Processing 1.96 × 10-67 5.81 × 10-128
Myometrial Relaxation and Contraction Pathways 6.88 × 10-45 2.64 × 10-63
Nucleotide Metabolism 0.11 4.05 × 10-17
p63Transcription Factor Network 3.55 × 10-31 8.67 × 10-72
Spliceosome Prp19/CDC5L complex 6.13 × 10-4 3.20 × 10-9
Vitamin C in the Brain Pathway 0.36 3.39 × 10-14
Note: p-value is derived from c2Goodness of Fit
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When we tried to group pathways by de novo PPI, all 7
pathways (■) listed in Table 3 were grouped together.
As indicated by the different divisions, each method
determines unique clusters, however, it is clear some of
these p53 related pathways serve similar functions
across different concept consolidation methods. Specifi-
cally, “Direct p53 effectors” and “p53 pathways” are
always grouped together, with “p53 signaling pathway”
possibly included in this group. By finding pathway con-
cepts based on a variety of gene attributes, different
functional connections are determined between the
pathways.
MMS case study
To demonstrate the capability of examining gene sets at
pathway level, we also tested a second gene set that
mimic the effect of cisplatin-induced DNA damage and
inhibition of DNA synthesis. Ravi et al. [27] used a cell-
based RNAi screen against the Drosophila genome and
the alkylating agent methyl methanesulphonate (MMS).
The screen determined a resultant set with 996 Droso-
phila genes required for DNA damage survival. Using
this gene set they identified 13 pathways integral to
DNA damage response. To compare their pathway ana-
lysis between two studies, we used Ensembl [28] to con-
vert the Drosophila genes to 964 NCBI Entrez GeneIDs
for the human orthologs.
The pathways found to be integral to DNA damage
response included Base excision repair, Nucleotide Exci-
sion Repair, Mismatch Repair, Homologous Recombina-
tion Repair, RecQ helicases, DNA damage response,
Proteasome, Glutathione Synthesis, TOR pathway, Basal
Transcription, Ribosome, ATPase, and Notch signaling
pathway. All of the pathways had equivalent human
Table 3 P53 overlapping cluster membership
Pathway Name, (enrichment p-value) de novo Gene
Membership
de novo Gene
Ontology
de novo Protein
Interactants
Weighted
Consolidation
Enrichment
Consolidation
Direct p53 effectors, (p = 1.16 × 10-9) ■ ■ ■ ■ ■
p53 pathway, (p = 6.19 × 10-9) ■ ■ ■ ■ ■
p53 signaling pathway, (p = 9.84 × 10-7) ▲ ■ ■ ▲ ■
p53-dependent G1 DNAdamage
response, (p = 0.15)
● ● ■ ▼ n/a
p53-dependent G1/S DNA damage
checkpoint, (p = 0.15)
● ● ■ ▼ n/a
p53-independent DNA damage response,
(p = 0.25)
● ● ■ ● n/a
p53-independent G1/S DNA damage
checkpoint, (p = 0.25)
● ● ■ ● n/a
Note: matching symbols in a column indicate shared cluster membership. n/a indicates non-enriched pathway not included in any cluster. Dividers and matching
symbols indicate pathways groups within a consolidation method.
Table 4 RNAi resultant gene set overlapping cluster membership
Pathway Name, (enrichment p-
value)
de novo Gene
Membership
de novo Gene
Ontology
de novo Protein
Interactants
Weighted
Consolidation
Enrichment
Consolidation
Base excision repair (p = 0.58) ■ ● ■ ■ n/a
Mismatch Repair (p = 0.75) ■ ● ■ ■ n/a
Homologous Recombination
Repair (p = 0.73)
■ ■ ■ ■ n/a
DNA damage response (p = 0.09) ■ ■ ■ ■ n/a
Nucleotide Excision Repair (p =
1.99 × 10-4)
■ ■ ■ ▲ ■
Proteasome (p = 3.4 × 10-3) ■ ■ ■ ► ▲
Basal Transcription (p = 2.97 × 10-
11)
■ ■ ■ ◄ ►
Ribosome (p = 6.65 × 10-3) ■ ■ ■ ♦ ▼
TOR pathway (p = 2.90 × 10-3) ▲ ■ ■ ▼ ●
Notch Signaling Pathway (p = 3.05
× 10-4)
▲ ■ ■ ◘ ◄
Glutathione Biosynthesis (p = 0.11) ► ► ► ● n/a
Note: RecQ helicases and ATPase were not found among the human pathways. p-values are derived from one-tail Fisher’s Exact test, before multiple test
correction. Dividers and matching symbols indicate pathways groups within a consolidation method.
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pathways except for RecQ helicases and ATPase. Using
their resultant fly gene set converted to human ortho-
logs we found enrichment scores for each, described in
Table 4. Together with EC and WC, we performed de
novo consolidation method with a cut-off of 100 clus-
ters. In Table 4, we show each pathway’s membership
for clusters formed for each method. For de novo PPI,
all pathways except Glutathione Synthesis were found in
the same pathway concept (■). For de novo Member-
ship, Notch and Tor pathways formed a separate con-
cept (▲) and for de novo GOSlim, Base excision repair
and Mismatch Repair formed a separate concept (●). EC
separated everything into different clusters. WC com-
bined Base excision repair, Mismatch Repair, Homolo-
gous Recombination Repair and DNA damage response
(■) and separated every other pathway.
HPD comparison
Chowbina et al. [14] determine 25 HPD pathways that
contain some combination of the BRCA1, FOXA1 and
STK6 genes. We downloaded their Pathway List and
Pathway - Pathway Similarity Scores and by hand, found
7 pathway pairs with similarity score of 0.47 or higher
among 9 of the original 25 pathways. Their similarity
score is derived from pathway similarity based on path-
way components (see reference for details). The pathways
were Aurora A signaling (NCI-Nature), Signaling by Aur-
ora kinases (NCI-Nature), Aurora B signaling (NCI-Nat-
ure), FOXA transcription factor networks (NCI-Nature),
FOXA1 transcription factor network (NCI-Nature),
FOXA2 and FOXA3 transcription factor networks (NCI-
Nature), ATRBRCA_PATHWAY (Biocarta), and Fanconi
Anemia pathway (Reactome). Indicated in Table 5
Table 5 HPD gene set overlapping cluster membership
Pathway Name, (enrichment p-value) HPD
similarity
grouping
de novo Gene
Membership
de novo
Gene
Ontology
de novo
Protein
Interactants
Weighted
Consolidation
Enrichment
Consolidation
Aurora B signaling (p = 1.32 × 10-2) ■ ▲ ■ ▲ ▲ ■
Aurora A signaling (p = 1.39 × 10-4) ■ ■ ■ ■ ■ ■
Signaling by Aurora kinases (p = 3.27 × 10-4) ■ ■ ■ ■ ■ ■
FOXA transcription factor networks (p = 2.23 ×
10-4)
● ● ■ ● ● ■
FOXA1 transcription factor network (p = 6.53 ×
10-5)
● ● ■ ● ● ■
FOXA2 and FOXA3 transcription factor
networks (p = 1.38 × 10-2)
● ● ■ ♦ ♦ ■
Fanconi Anemia pathway (p = 8.36 × 10-3) ▲ ▼ ► ► ► ■
ATRBRCA_PATHWAY (p = 6.75 × 10-3) ▲ ► ► ► ► ■
ATM mediated phosphorylation of repair
proteins (p = 1.93 × 10-3)
► ► ► ▼ ► ■
Recruitment of repair and signaling proteins to
double-strand breaks (p = 2.58 × 10-3)
► ► ► ▼ ► ■
Note: p-values are derived from one-tail Fisher’s Exact test, before multiple test correction. Dividers and matching symbols indicate pathways groups within a
consolidation method.
Table 6 TP53 overlapping cluster membership
Pathway Name, (enrichment p-value) HPD similarity
grouping
de novo Gene
Membership
de novo Gene
Ontology
de novo Protein
Interactants
G1 to S cell cycle control (p = 7.30 × 10-3) ■ ■ ■ ■
G2_PATHWAY (p = 2.58 × 10-3) ▲ ▲ ■ ■
Class I PI3K signaling events mediated by AKT
(p = 0.14)
● ▼ ▲ ■
DNA damage response (p = 7.20 × 10-3) ● ● ▲ ■
MAPK signaling pathway (p = 2.88 × 10-2) ● ► ▲ ■
Glioma (p = 6.70 × 10-3) ► ► ▲ ■
Non-small cell lung cancer (p = 5.80 × 10-3) ► ► ▲ ■
Melanoma (p = 7.63 × 10-3) ► ► ▲ ■
Endometrial Cancer (p = 5.59 × 10-3) ► ► ▲ ■
Note: p-values are derived from one-tail Fisher’s Exact test, before multiple test correction. Dividers and matching symbols indicate pathways groups within a
consolidation method.
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column 1, using HPD’s similarity score, we grouped the
Aurora, FOXA, ATRBRCA/Fanconi Anemia, and ATM/
Repair of double-strand breaks pathways. Pathway Distil-
ler finds 110 pathways that contain some combination of
the BRCA1, FOXA1 and STK6 genes and 53 of them are
enriched with a p-value less than 0.05. We tested if the
different consolidation methods will cluster the 9 path-
ways like HPD. Described in Table 5, membership500
was the most similar to HPD’s similarity group, exactly
matching the FOXA and ATM/Repair of double-strand
breaks pathways (●, ►). This similarity is to be expected
because both HPD and Membership use gene set similar-
ity as the scoring mechanism. Highlighted in the remain-
ing columns of Table 5, Pathway Distiller’s other methods,
each utilizing different similarity measurements, find
slightly different pathway groups.
We also extended our analysis of TP53 by compared
HPD and Pathway Distiller’s analysis of a single gene by
searching on “p53” in HPD and inputting a file with
“7157” in Pathway Distiller. Both yield all pathways that
contain TP53. For HPD, we determined 20 pathways that
group together into 6 clusters. By manual name compari-
son, we determined pathways similar to 9 of HPD’s path-
ways. Described in Table 6, the 9 Pathway Distiller
pathways map to four different HPD similarity groups (■,
▲, ●, and ►). The cell cycle pathways were not grouped
with any of the other pathways. The AKT, DNA repair
and MAPK pathways were grouped. Finally all of the
disease related pathways were grouped. Our de novo
Membership, was most similar to HPD’s groups and PPI
the least similar, grouping all 9 pathways (■) together.
Only the de novo methods were included in Table 6
because with a single gene resultant gene set, by defini-
tion, EC and WC will group all pathways.
Discussion
Merging several pathway data sources allows for better
coverage of existing information but is difficult because of
the heterogeneous nature of the member pathways. A sim-
ple solution reduces the information for each pathway to
its gene members. While this loses information that could
be used to cluster pathways like directionality, we see that
our consolidation methods achieve consolidation both de
novo and with the experimentally focused data. The result-
ing pathway concepts are made up of pathways that have
been found to share some functional characteristics. Using
various methods for consolidation enables different views
of the same data. For example, PPI and WC offer users
consolidation based on interactions which could provide
mechanisms for understanding how pathways are inter-
connected within a single concept. GOSlim on the other
hand, focuses on functional connections according to
GO Ontology annotations. Even within a single de novo
method we provide various cut-offs that can find general
to very specific measured similarities between pathways
within a cluster. As each method has strengths, they also
have weaknesses. The EC method is limited to only
enriched pathways and will miss any non-enriched path-
way. Because the other methods utilize a single measure-
ment to assess similarity, they will sometimes miss
connections that exist when the measurement does not fit
the data.
For most research, EC and WC will provide the best
overview of pathway concepts related to experiment speci-
fic enriched pathways and all pathways. Because EC is
tightly aligned with enrichment results researchers inter-
ested in only connections between enriched pathways will
typically rely on this method. However because WC
includes non-enriched pathways, it is possible to find con-
nections between enriched and non-enriched pathways.
Discussed further later, we saw that WC failed for
Methionine Degradation I in our random testing even
when the testing was based on interactions. This was
due to the lack of interactions between the few gene
members. However as we also saw in Table 2, this fail-
ure was mitigated by the successful concept develop-
ment of the same pathway using EC. While we
recognize that the goal of many pathway analysis tools
is to find a single results and some confidence score,
Pathway Distiller seeks to facilitate exploration of var-
ious results to aid a user in finding distinct functional
connections between pathways in a pathway concept.
Pathway Distiller’s supplied resultant gene set (cispla-
tin resultant gene set) is a good example of one of the
challenges that our pathway enrichment consolidation
addresses. The 177 pathways with p-values ≤ 0.05 are
difficult to draw conclusions from. Shown in Table 1,
the Enrichment Consolidation (EC) method reduces this
to 12 pathway concepts, each represented by the most
enriched among the pathways consolidated. This enables
focused attention and readability. While the EC method
only groups enriched pathways, the Weighted Consoli-
dation (WC) method groups all pathways with at least
one resultant gene. Out of the 2,462 human pathways,
for example, there are 1,456 pathways with one of the
cisplatin resultant genes that results in 318 pathway
concepts. While this is too large compared with the EC
method, it offers a different pathway description preci-
sion of the resultant gene set. Because it is not limited
to enriched pathways, enriched and not enriched path-
ways are combined. Our web-based Pathway Distiller’s
result tables are column sortable and therefore we are
able to find the lowest p-value for each pathway con-
cept. In the case of cisplatin resultant gene set, there are
71 pathway concepts with at least one enriched pathway,
much larger than 12 pathway concepts generated by EC
method however small enough to browse for interesting
information.
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Often it is important to incorporate specific enrich-
ment values within a single experimental design, for
instance across time points in a single cell line treated
with a compound. But among diverse experiments the
most enriched pathway in one might have no relationship
to another experiment. A de novo method for consolidat-
ing pathways independent of specific experiments that
still handles the problems of set matching and numerical
identification of subset similarity allows empirical com-
parison and consistent results. Like the WC method,
both enriched and non-enriched pathways are included,
however all gene members of each pathway were used to
determine clusters, not only the resultant genes. Table 1
highlights the variation between the clustering methods
and within the de novo methods with different cut-off
values.
Measuring the number of interactions among a set of
genes gives an estimation of their functional relatedness.
The probabilities in the first column of Table 2 indicates
that the interactions are unique among most pathway
concepts and not due to random sampling of genes for
the pathway concept found using the EC method. Clearly,
in almost all of the cases, the pathway concepts are not
combined without some relationship among the path-
ways as measured by interactions. The second column
measures the randomness of the interactions in the
matching clusters of the WC method. This method of
validation fails for three of the pathway concepts we
tested, two in EC and one in WC. This illustrates well
the advantage of not using a “one size fits all” approach
to consolidation. The two pathway concepts that fail for
EC (Nucleotide Metabolism and Vitamin C in the Brain
Pathway) both have few pathway gene members (6 and 4
respectively) and few interactions (1 and 0 respectively).
Both matching clusters were significant for the WC
method because each concept contains a slightly different
set of member pathways. Interestingly, Methionine
Degradation I (to homocysteine) fails in WC but was sig-
nificant in EC again due to a slightly different set of
member pathways. It is surprising that it fails in the
interaction based validation when it was clustered due to
weighted interactions until it is considered that there was
only a single interaction among the genes in the concept,
and this one interaction was very specialized to the path-
way members of the concept.
Tables 3, 4, 5, 6 highlight the strengths of our consoli-
dation methods. The tables should be read in a column-
wise format; they include dividers to facilitate this. In
other words, the divisions show how one clustering
methods groups the pathway rows. Each division config-
uration represents a different way to cluster the rows of
pathways.
From Table 3, one would expect grouping of pathways
with a common relationship to p53. Gene Ontology
divides the 7 pathways into two different clusters and the
two different clusters have significance in terms of nor-
mal cells and those dealing with DNA damage response.
Protein Interactions and the EC method group all path-
ways together. Gene Membership and WC method group
the 7 pathways into three and four pathway concepts
respectively. The WC method follows the grouping of the
Gene Membership except it separates the p53-dependent
and p53-independent pathways, clearly offering different
precision of pathway representation.
Not only does pathway consolidation make the data
more manageable, readable and publishable, it could
focus attention to pathways not previously considered.
For example, Ravi et al. [27] determined 13 pathways
related to DNA damage response, 11 corresponding
human pathways are shown in Table 4. Similar to their
findings, when we utilized the human ortholog resultant
gene set for their RNAi screen, not all of the pathways
were enriched, therefore simple enrichment methods
would fail to draw attention to one of these pathways.
Our different but complementary consolidation methods
can group both enriched and non-enriched pathways
together. For example, Gene membership100 finds Base
excision repair, Nucleotide Excision Repair, Mismatch
Repair, Homologous Recombination Repair (HRR) and
DNA damage response all together in a single concept
(■). Only Nucleotide Excision Repair would have been
apparent in the initial pathway enrichment step with a p-
value of 1.99 × 10-4. But, by looking at pathways also
clustered with Nucleotide Excision Repair in the Consoli-
dation Results grid, one might find connections between
enriched and non-enriched pathways. Ravi et al. created
a similar hypothesis of connections between these path-
ways by hand. In this example, all pathways except for
Glutathione Metabolism are contained in the same con-
cept in at least one method and some are in the same
concept for all methods. Because Glutathione Metabo-
lism is never clustered with the other pathways this offers
a chance for exploration of the differences between Glu-
tathione Metabolism and the other pathways. Similarly,
the possible functional connections between Notch and
Tor pathways (membership100) and Base Excise Repair
and Mismatch repair (PPI100) might lead to novel ave-
nues for research.
Pathway Distiller found 53 and 105 enriched pathways
when processing the MMS and TP53 case studies, respec-
tively. Functional connections in the form of interactions,
gene membership and GO Ontology between pathways
will enable users to focus attention on meaningful groups
instead of many individual members.
Table 5 shows that the FOXA, FOXA1 and FOXA2/
FOXA3 pathways were grouped by HPD. Figure 4 illus-
trates the overlapping nature of the FOXA transcription
factor network and the FOXA1 transcription factor
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network. HPD and Pathway Distiller’s membership500
combined the three pathways into a single cluster, how-
ever PPI500 and WC did not. As indicated in the figure
there is some amount of overlap between the three path-
ways. The FOXA1 gene is connected to the network
through a single gene, AR. AR is not included in the
FOXA2/FOXA3 transcription factor network. Because
HPD and membership500 rely on overlap of gene sets, it
is not surprising that the cluster contains all three path-
ways. Conversely, the interaction-based methods split the
pathways into different concepts and in this case because
of the functional importance of AR.
In the second comparison with HPD, their similarity
scores placed MAPK signaling pathway and the cancer
pathways into different clusters. MAPK signaling path-
way was included in the cancer related cluster for Path-
way Distiller’s membership500 cluster. Pathway Distiller
also includes Bladder, Colorectal cancer, Pancreatic
cancer, Chronic myeloid leukemia, Thyroid, Prostate,
and small cell lung cancers. Dhillion et al. [29] describe
how MAPK features prominently in cancer. In retro-
spect, the membership500 cluster could have hinted at
the same conclusion.
Conclusions
Pathway enrichment is an important tool when making
sense of gene expression data, however the information
must be in a form conducive to examination and evalua-
tion. Each of the publically available pathway data
sources has strengths and weaknesses. In order to
exploit the information, the combination of these data
sources is essential, but only if we can avoid overlapping
and maintain the independence between the pathway
concepts. The proposed pathway consolidation is impor-
tant to make the combined data manageable, but still
accurately describing the original data. Three methods
Figure 4 Interaction network for FOXA, FOXA1 and FOXA2/3 transcription factor networks. FOXA1 and AR interaction is noted (present/
missing) to highlight if AR is in pathway or not.
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were discussed in the paper: one focusing on pathways
determined enriched in a given experiment, another
looks at both enriched and non-enriched pathways, but
using only the experiment’s resultant genes, and the
final grouping the pathways in a de novo, experiment
independent manner. In addition, the web-based Path-
way Distiller implementation (http://cbbiweb.uthscsa.
edu/PathwayDistiller/) will enable access to a variety of
pathway data sources, pathway enrichment given resul-
tant gene sets and our diverse consolidation methods.
The default option consolidation method, Enrichment
Consolidation and Weighted Consolidation, are the
most descriptive representation of the enrichment
results, but the other methods offer additional views of
the results focusing on gene annotation information and
the overlap of enriched and non-enriched pathways
within concepts.
Pathway Distiller will benefit a scientist who needs a
simple-to-use yet sophisticated pathway consolidation
and enrichment method to find functional insight for
their genotypic data. It allows them to use four steps to
retrieve concept grouping and then the additional ability
to further explore concept relationships if desired.
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